Wiley acquires SimBioSys

John Wiley & Sons has acquired SimBioSys, a provider of scientific software tools that facilitate the drug discovery process.

SimBioSys is described as a pioneer in the field of computer-aided retrosynthetic analysis where it supports chemists in the challenges of organic synthesis. It was founded in 1996, privately held, and is based in Toronto, Canada.

'Wiley has deep roots in top quality chemistry publishing with high-profile international chemistry society partnerships and extensive chemical databases, journals, books and references,' said Steve Miron, senior vice president of Wiley’s Global Research business. 'By combining our traditional published content and databases with machine learning algorithms, we can support chemists in innovative research as they advance world knowledge.'